Substance / Medication

Etanercept

Overview

Active Ingredient
etanercept
RxNorm CUI
214555
Labeler: Immunex CorporationUpdated: 2025-12-09T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Enbrel is contraindicated in patients with sepsis.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

78 trials linked to this intervention

78
Total Trials
5
Recruiting
41
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy, safety, and immunogenicity of biosimilars compared with the biologic etanercept in patients with rheumatoid arthritis: a systematic review and meta-analysis.
Andrade Aurélio Matos, da Motta Girardi Juliana, da Silva Erica Tatiane et al. · Syst Rev · 2024
PMID: 39605094Meta-AnalysisFull text (PMC)
Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis.
Carrascosa Jose Manuel, Rebollo Francisco, Gómez Susana et al. · J Dermatolog Treat · 2018
PMID: 29671665Meta-Analysis
Efficacy and safety of etanercept in the treatment of sciatica: A systematic review and meta-analysis.
Jing Shangfei, Yang Chenyuan, Zhang Xiaofei et al. · J Clin Neurosci · 2017
PMID: 28779960Meta-Analysis
Etanercept for treating axial spondyloarthritis.
Guillot Xavier, Prati Clément, Sondag Maxime et al. · Expert Opin Biol Ther · 2017
PMID: 28682112Meta-Analysis
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
Duarte Ana, Mebrahtu Teumzghi, Goncalves Pedro Saramago et al. · Health Technol Assess · 2017
PMID: 29105621Meta-AnalysisFull text (PMC)
DOSAGE AND DURATION OF ETANERCEPT THERAPY FOR ANKYLOSING SPONDYLITIS: A META-ANALYSIS.
Lee Heeyoung, Jung Younjoo, Song Seungyeon et al. · Int J Technol Assess Health Care · 2017
PMID: 28434410Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Etanercept (substance)
SNOMED CT
387045004
UMLS CUI
C0717758
RxNorm CUI
214555
Labeler
Immunex Corporation

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

4
Conditions
2
Biomarkers
1
Specialists
0
Symptoms
78
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.